| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
EDUCATIONAL REVIEW |
From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Correspondence: Address correspondence and reprint requests to: Ronald P. DeMatteo, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; Fax: 212-639-4031; E-mail: dematter{at}mskcc.org
ABSTRACT
Abstract: Although gastrointestinal stromal tumor (GIST) is the most frequent mesenchymal neoplasm of the gastrointestinal tract, until recently it has been an obscure disease. Now, there is widespread scientific and clinical interest in GIST because its principal pathogenetic defect has been identified and a specific molecular inhibitor of GIST has been developed. Most GISTs contain a gain-of-function mutation in the c-kit proto-oncogene. Mutation results in constitutive activation of the Kit receptor tyrosine kinase, which induces cellular proliferation. STI571 is an oral agent that selectively inhibits Kit. It is a landmark development in cancer treatment and marks a new era of targeted molecular therapy. Its efficacy proves that a specific inhibitor can counteract the effects of a genetic defect responsible for neoplasia. Although STI571 was first applied to GIST only 2 years ago, it has already revolutionized the treatment of patients with metastatic disease and is also currently being tested as an adjuvant therapy after the resection of primary GIST.
Key Words: Gastrointestinal stromal tumor • GIST • c-kit Proto-oncogene • STI571
This article has been cited by other articles:
 |
|
 |
|
  A. Fernandez, A. Sanguino, Z. Peng, A. Crespo, E. Ozturk, X. Zhang, S. Wang, W. Bornmann, and G. Lopez-Berestein Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 589 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fernandez, A. Sanguino, Z. Peng, A. Crespo, E. Ozturk, X. Zhang, S. Wang, W. Bornmann, and G. Lopez-Berestein Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target Cancer Res., May 1, 2007; 67(9): 4028 - 4033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hong, H. Choi, E. M. Loyer, R. S. Benjamin, J. C. Trent, and C. Charnsangavej Gastrointestinal Stromal Tumor: Role of CT in Diagnosis and in Response Evaluation and Surveillance after Treatment with Imatinib. RadioGraphics, March 1, 2006; 26(2): 481 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ferrari, M. Casanova, P. Collini, C. Meazza, R. Luksch, M. Massimino, G. Cefalo, M. Terenziani, F. Spreafico, S. Catania, et al. Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan J. Clin. Oncol., June 20, 2005; 23(18): 4021 - 4030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sandrasegaran, A. Rajesh, J. Rydberg, D. A. Rushing, F. M. Akisik, and J. D. Henley Gastrointestinal Stromal Tumors: Clinical, Radiologic, and Pathologic Features Am. J. Roentgenol., March 1, 2005; 184(3): 803 - 811. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weitz, C. R. Antonescu, and M. F. Brennan Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time J. Clin. Oncol., July 15, 2003; 21(14): 2719 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Machida, B. J. Mayer, and P. Nollau Profiling the Global Tyrosine Phosphorylation State Mol. Cell. Proteomics, April 1, 2003; 2(4): 215 - 233. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
